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A B S T R A C T
Microfocus synchrotron x-ray ﬂuorescence (SXRF) imaging focussed on detection of the Os LIII edge shows that
the organo‑osmium metallodrug candidate [(ŋ6-p-cym)Os(Azpy-NMe2)I]+ (p-cym= p-cymene, Azpy-NMe2= 2-
(p-([dimethylamino]phenylazo)pyridine)) [1] penetrates eﬃciently into the interior of A2780 human ovarian
cancer cell spheroids, a model for a solid tumour. The accompanying changes in Zn and Ca distribution suggest
that the complex causes nuclear damage and initiates signalling events for cell death, consistent with ﬁndings for
cultured cancer cell monolayers. Such tumour penetration is likely to be important for combatting resistance to
chemotherapy, which is becoming a problem for current clinical platinum drugs.
There is a clinical need for new anticancer treatments capable of
overcoming platinum resistance [1]. New generations of drug candi-
dates with novel mechanisms of action need to penetrate into the in-
terior of tumours since this is likely to be a major factor in determining
resistance to chemotherapy [2]. Hence, metallodrug candidates should
be capable of reaching the core of treated tumours.
Organometallic Ru, Ir and Os-‘piano-stool’ complexes are a class of
compounds with promising anticancer properties [3–13]. In particular,
[(ŋ6-p-cym)Os(Azpy-NMe2)I]+ (p-cym= p-cymene, Azpy-NMe2=2-(p-
([dimethylamino]phenylazo)pyridine)) [1] (Chart 1) exhibits potent
activity towards a wide range of cancer cell lines. It has a diﬀerent
mechanism of action to cisplatin and is capable of overcoming re-
sistance to clinical platinum drugs in vitro. It also shows promising
antitumour activity in vivo [14,15].
We have demonstrated that 1 is a relatively inert prodrug that can
be activated by hydrolysis of the OseI bond under intracellular re-
ductive conditions, generating the more reactive OseOH adduct [1-
OH]. Interestingly, the chlorido analogue [1-Cl], behaves similarly to
1, but hydrolyses more rapidly, and is 10× less active in inhibiting the
proliferation of cancer cells [16]. Complex 1 rapidly generates large
quantities of reactive oxygen species (ROS) inside cells through mi-
tochondrial pathways [17,18]. Using synchrotron X-ray ﬂuorescence
(SXRF), we showed that osmium from 1 is concentrated in small
organelles within the cytosol of treated cells, possibly mitochondria,
leading to extensive nuclear damage, and mobilisation of Ca from the
endoplasmic reticulum (a signalling event for cell death) [19].
The interaction of 1 with solid tumours has yet to be investigated.
Here we use 3D spheroids as tumour models that can be readily cul-
tured in vitro [20,21]. They provide useful systems for the study of
tumour growth inhibition and drug penetration. Tumour penetration by
metallodrugs has been studied by SXRF [22–24] and other techniques
such as Laser Ablation Inductively Coupled Plasma Mass Spectrometry
(LA-ICP-MS) [25] or Matrix-Assisted Laser Desorption/Ionization Mass
Spectrometric Imaging (MALDI-MSI) [26] which allow direct mapping
of metals in biological samples, including 3D spheroid solid tumour
models.
We have acquired SXRF elemental maps of A2780 human ovarian
carcinoma spheroids to study the ability of organo‑osmium drug can-
didate 1 to penetrate into solid tumours and its eﬀect on the distribu-
tion of natural metal ions.
A2780 ovarian carcinoma 3D spheroids were generated by growing
cells for 5 days in U-bottom cell-repellent 96 well plates. The size of the
tumour models was controlled by altering the initial cell density.
1000–5000 cells/well yielded spheroids with a diameter
406 ± 6 μm–560 ± 8 μm (Fig. S1). For tumour growth inhibition as-
says, 2500 cells were seeded and grown for 3 days, yielding spheroids of
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275 ± 6 μm diameter. They were exposed to 1 for 16–48 h, and ATP
content was measured using a luminescence assay to determine cell
viability in the 3D spheroids. Cisplatin and 1-Cl (Cl analogue of 1) were
studied for comparison. The antiproliferative activity of complexes was
also determined in monolayer cultures treated with the drugs for the
same times (Tables 1 and 2, Fig. S2).
Our experiments show that 1 is highly eﬀective in inhibiting tumour
growth, being over 50× and 15× times more active than cisplatin and
1-Cl (after 48 h treatment), respectively. As expected, this pattern is
also observed for cell monolayers treated with these complexes.
Interestingly, increases in the time of exposure of both 2D and 3D
cultured cells to 1 (from 16 h to 48 h) led to comparable increases in
antiproliferative activity: 8× and 7× times more active in cell mono-
layers and spheroids, respectively. This was not observed when cells
were treated with cisplatin or 1-Cl; longer exposure times led to dra-
matically higher improvements in the biological activity of cisplatin
and 1-Cl in cell monolayers compared to 3D spheroids (Fig. S3).
Overall, this suggests that 1 penetrates into spheroids in an eﬃcient
time-dependent way. To investigate this, microfocus x-ray ﬂuorescence
imaging experiments were carried out to map the distribution of os-
mium in the spheroids.
Synchrotron x-ray ﬂuorescence (SXRF) was used to study the tu-
mour spheroid penetration properties of osmium from complex 1 in
A2780 spheroids treated with 0.7 μM 1 (½xIC50-sph) for 0, 16, 24 and
48 h. Cells were ﬁxed with glutaraldehyde, dehydrated with ethanol
and embedded in resin for ultramicrotomy. Chemical ﬁxation is not
ideal for the preservation of biologically relevant elements in adherent
mammalian cells [27], but it is required to produce thin sections for
elemental analysis of spheroids and tissues. Elemental maps of 500 nm-
thick sections of each sample were acquired on beamline I18 (DIA-
MOND Light Source, UK) [28]. The beam was focused to a 2×2 μm2
size, and energy ﬁxed at 12 keV to achieve excitation of the Os LIII-edge.
The presence of Os in samples treated with 1 was conﬁrmed by de-
tection of the Os LIII X-ray ﬂuorescence emission lines (Fig. S4).
Interestingly, the results suggest that 1 penetrates into the tumour
core, and remains there for longer than expected. Although the back-
ground contribution could not be totally eliminated by peak ﬁtting,
maps of 300×300 μm2 areas of interest (ROIs) collected from the
diﬀerent samples (step size 2× 2 μm2, dwell time 1 s; Fig. 1, Figs.
S5–S8) showed that there is a direct relation between cell treatment
time and tissue penetration of the complex (Figs. 1–2, Fig. S6). 1 oc-
cupies similar areas of the spheroids after 24 h and 48 h treatment.
About 18% of the area studied contained Os (Fig. S9). However, Os
penetrates more deeply into the tumour model (Fig. 2), and is accu-
mulated more after 48 h > 24 h > 16 h, with levels of
6.4 ± 1.6 > 4.8 ± 0.7 > 0.11 ± 0.02 pg Os/section respectively
(Fig. S10). In contrast, cell monolayers showed maximum uptake of 1
after 24 h incubation, followed by a rapid decrease in the amount of Os
inside cells during the next 48 h [29]. Diﬀerences in the accumulation
kinetics of 1 between cell monolayers and 3D tumour models may result
from more eﬀective eﬄux from cell monolayers, or slow diﬀusion of the
drug into tissue-like samples.
The correlation between incubation time and amount of Os at the
core of the spheroids, suggests that 1 is internalised by transcellular
transport mechanisms. This means that the drug would be taken up by
cells at the surface of the tumour and then moves towards more internal
areas, being activated in the process. To investigate this, X-ray
Absorption Spectroscopy (XAS) spectra were collected in areas with
relatively high concentrations of Os within diﬀerent parts of the
spheroids. Well deﬁned X-ray Absorption Near Edge Structure (XANES)
and weak Extended X-Ray Absorption Fine Structure (EXAFS) for Os
were observed (Fig. 3). However, S/N ratio was too low, most likely due
to the low concentration of Os in the sample, and did not allow the
meaningful ﬁtting of the spectra. Attempts to use longer or multiple
acquisitions to increase the S/N ratio led to a rapid decrease in the
intensity of the XAS spectra, even when attenuators were used. This is
likely to be due to beam damage of the sample, and hampered use of
XAS to study the cellular speciation of 1.
Treatment of spheroids with 1 also led to extensive changes in Zn
and Ca distribution, from being discretely localised in untreated sam-
ples to being more widely distributed in treated spheroids (Fig. 1, Fig.
S7-S8). This change in distribution was time-dependent. After 16 h
exposure to the drug, some Zn and Ca are still discretely localised in
certain areas of the spheroids, whereas after 24 or 48 h incubation, they
are more evenly distributed. This is probably not the result of an in-
crease in metal leaching from spheroids during sample preparation, as
the total amount of Zn remained mostly unchanged across the diﬀerent
Chart 1. Structures of [(ŋ6-p-cym)Os(Azpy-NMe2)I]+ [1] and related com-
plexes.
Table 1
Growth inhibition (IC50-sph μM) of A2780 human ovarian carcinoma 3D
spheroid tumour models.
IC50-sph (μM) exposure time
Complex 16 h 24 h 48 h
Cisplatin 191 ± 9 108 ± 8 79.8 ± 0.2
1-Cl 86 ± 4 47 ± 2 22.3 ± 0.3
1 9.7 ± 0.3 3.5 ± 0.6 1.43 ± 0.04
Table 2
Antiproliferative activity (IC50 μM) towards monolayers of A2780 human
ovarian carcinoma cancer cells.
IC50 (μM) exposure time
Complex 16 h 24 h 48 h
Cisplatin 90 ± 11 23.7 ± 0.7 15 ± 0.9
1-Cl 14 ± 1 5.5 ± 0.4 2.0 ± 0.02
1 0.8 ± 0.2 0.5 ± 0.1 0.10 ± 0.01
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samples, while the quantity of Ca found in the sections increased after
spheroids were treated with 1 (Fig. S10). The changes observed in the
Zn and Ca maps of spheroids are in good agreement with those
observed for monolayer cultured cells treated with the drug. Overall,
these alterations suggest the presence of nuclear damage with Ca re-
lease from the endoplasmic reticulum (ER), possibly indicating pro-
grammed cell death. The presence of abnormally high sub-G0 popula-
tions in cell cycle studies is consistent with this. However, no
mitochondrial loading with Ca is observed, suggesting that 1 does not
induce apoptosis, and the mechanism of cell death remains to be further
eliucidated [19].
Our microfocus x-ray ﬂuorescence experiments on Diamond syn-
chrotron beamline I18 have provided new insights into the interaction
of organo‑osmium drug candidate 1 with solid tumours. The SXRF maps
show that the Os drug penetrates eﬃciently into tumour spheroids,
although more complicated models would be required to mimic the
heterogeneous nature of solid tumours. Complex 1 is more eﬀective
than cisplatin in inhibiting tumour growth in vitro, and it has a diﬀerent
mechanism of action in cells compared to current platinum drugs. Our
results highlight the potential of 1 as a candidate for further develop-
ment as a clinical drug to treat platinum resistant tumours, a current
clinical need.
Fig. 1. Bright ﬁeld images and SXRF elemental maps of Os, Ca and Zn in A2780 human ovarian carcinoma spheroid sections (500 nm-thick) treated with 0.7 μM 1 (½
IC50) for 0, 16, 24 or 48 h. Raster scan: 2× 2 μm2 step size, 1 s dwell time. Scale bar 100 μm. Calibration bar in ng mm−2. Yellow squares in bright ﬁeld images
indicate areas of the spheroid studied using SXRF. Red areas in SXRF elemental maps indicate the limits of the spheroids.
Fig. 2. Average Os content (in ng mm−2) as a function of distance from A2780
3D spheroid surface, after treatment for 16 h (purple), 24 h (red) or 48 h (green)
with 0.7 μM 1.
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